Study of High Heated Humidity Using the Airvo 2 Device to Reduce Mucositis in Patients Undergoing Autologous Stem Cell Transplant for Blood Cancers

What this Trial Is About

Researchers are evaluating the effects of high heated humidity on mucositis in patients undergoing autologous stem cell transplant for hematologic cancers such as Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. This phase II, open-label, randomized clinical trial compares high heated humidity delivered by the Airvo 2 device to the current standard of care. Mucositis and other aerodigestive tract complications commonly occur during high-dose chemotherapy and stem cell transplant, often leading to longer, more complicated hospital stays. Participants are randomly assigned to one of two groups. One group receives standard care plus high heated humidity therapy using the Airvo device, which delivers warm, humidified air through nasal cannula for at least 4 hours daily starting on the day of transplant, typically for up to 14 days but possibly up to 30 days if mucositis persists. The other group receives standard care alone, which includes supportive therapies like oral hydration or medicated mouthwashes. The Airvo device is connected to a power outlet and worn continuously during treatment periods, with brief breaks allowed. Throughout the study, participants will be monitored for mucositis severity symptoms and assessments during treatment, up to 30 days. Researchers will also track secondary outcomes such as febrile neutropenia, infections acquired in the hospital, length of hospital stay, dietary intake, and changes in patient weight from admission to discharge. The study includes daily assessments while inpatients and aims to understand if heated humidity can reduce mucositis complications during stem cell transplant recovery.

High Heated Humidity in Stem Cell Transplant